Such findings have led to a placebo-controlled, double-blind phase 2b trial of hrACE2 in patients with severe COVID-19 [26]; however, no studies on the efficacy of ACE2 have been conducted to date on hamsters. This evidence concerns the gene ACE2 and COVID-19.